Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
CARB-X participants include Kevin Outterson, Executive Director, who will be leading the session “Surviving FDA Approval of your Antibiotic” on Wednesday April 21 at 9:25am ET / 6:25am PDT. He will touch upon:
- What can we learn from the past decade of FDA antibiotic approvals? •
- Niche markets where your drug can differentiate from generics
- Non-dilutive funding: CARB-X, BARDA, HERA
- Exit: AMR Action Fund, PASTEUR
CARB-X funded companies participating include Peptilogics, Vedanta, Antabio, Bioversys, ContraFect, Locus, Techulon, Summit, and MicuRx.
Click here to learn more.
Click here to view the event guide.
Click here to register.
More about the event here.